2023-506912-41-00CompletedPhase 1
A phase 1, randomised, double-blind, placebo-controlled, single ascending dose and multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics in healthy adult subjects after subcutaneous injection of TISA-818-Inj-5mg/mL.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 27 Nov 2023
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 18 Sept 2023
- Start date
- 9 Jan 2024
- Lead sponsor
- Enlitisa (Shanghai) Pharmaceutical Co. Ltd.
- EU CT number
- 2023-506912-41-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 48
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CTC Clinical Trial Consultants AB | Uppsala | Sweden | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.